Skip over main navigation
  • Log in
  • Basket: (0 items)
Hepatitis Australia
Listen
  • Search
  • Instagram
  • Twitter
  • Facebook
  • YouTube
Info line  Donate
Menu
  • About us
    • Who we are
    • Our Team
    • Our Board
    • Our Members
    • Corporate documents
    • Our website
    • Contacting Us
  • Hepatitis information
    • Liver Health
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C
    • Hepatitis Statistics
    • Other Languages
  • How to get help
    • COVID-19
    • Hepatitis Infoline
    • Your Rights and Responsibilities
    • For friends and family
    • Local hepatitis organisations
  • Get involved
    • Donate
    • Share your story
  • Our work
    • Hepatitis B Program
    • Hepatitis C Program
    • Policy and Advocacy
    • Our publications
    • World Hepatitis Day
    • If tatts could talk
  • News
    • Latest News
    • Media Releases
  • Workforce
    • Community
    • Professionals
    • Training Opportunities
  • Admin
    • Log in
  • Basket: (0 items)
  • NSW: Hepatitis A outbreak linked to imported clams

NSW: Hepatitis A outbreak linked to imported clams

19 September 2019

The NSW Food Authority is advising consumers who may have purchased salted or pickled clam products from Koryo Food Co. or Byul Mi Kim Chi to destroy any remaining product or return it for a refund.

Consumers should not consume these products.

Koryo Food Co. and Byul Mi Kim Chi have recalled these products due to a potential link with hepatitis A from salted or pickled clams imported from South Korea. Authorities in South

Korea recently issued an advisory warning consumers in that country to avoid certain types of salted or pickled clams, due to links with hepatitis A.

NSW Food Authority CEO, Lisa Szabo said testing was underway on a number of products but full results may take a number of weeks.

"Although a contamination has not yet been confirmed, we have advised the companies of a potential link to 8 cases of hepatitis A in NSW, and they have both undertaken a recall of the product," Dr Szabo said.

"We want to ensure all consumers who may have these products are aware of the possible link between the product and hepatitis A.

"While the affected products have been recalled from participating retailers, consumers may still have product they have already purchased in their fridges.”

Australian grown clams are not implicated in this outbreak.

Food products contaminated with hepatitis A virus may cause illness if consumed. Any consumers concerned about their health should seek medical advice, and should return the product to the place of purchase for a full refund.

Hepatitis A is a viral infection of the liver and is usually spread by consuming contaminated food or water or by direct contact with an infected person.

If you have consumed the affected product and are experiencing any symptoms of hepatitis A: fever, nausea, lack of appetite, abdominal pain, followed by dark urine, pale stools and jaundice (yellowing of the eyeballs and skin), please see your doctor for testing and treatment advice.

Anyone who has been previously vaccinated for hepatitis A is considered not at risk of infection.

The NSW Food Authority and NSW Health will continue to monitor the situation.

For more information, visit http://www.foodauthority.nsw.gov.au/news?t=3&y=2019&

More information about hepatitis A

Published: 19th September, 2019

Author: Kevin Marriott

Share this page
  • Email
  • Facebook
  • Twitter

Latest

  • Parliamentary Morning Tea: We can eliminate hepatitis C!

    Parliamentary Morning Tea: We can eliminate hepatitis C!

    The Parliamentary Friends Group for Action of Blood Borne Viruses Co-Chairs, Tim Wilson, MP and Senator Louise Pratt invite you to a Parliamentary Morning Tea on Thursday 12 November.

  • Renewed calls for Needle & Syringe Programs in prisons ahead of International Drug Users Day

    Renewed calls for Needle & Syringe Programs in prisons ahead of International Drug Users Day

    The Australian Injecting and Illicit Drug Users League (AIVL) and Hepatitis Australia are highlighting international calls for Needle and Syringe Programs (NSPs) in prisons, along with a greater focus on harm reduction initiatives, ahead of International Drug Users Day on 1 November.

  • Investment in hepatitis research needs to be accompanied by National Strategy implementation funding

    Investment in hepatitis research needs to be accompanied by National Strategy implementation funding

    6 October 2020 - Hepatitis Australia welcomes the Australian Government’s commitment to diverse hepatitis research, however we remain concerned that the 2019 Health Budget funding for hepatitis commitments is yet to hit the ground.

  • Investment in liver cancer medicines matched with prevention are changing Australian lives

    Investment in liver cancer medicines matched with prevention are changing Australian lives

    6 October 2020 - Hepatitis Australia welcomes the Australian Government’s significant investment of $230 million to expand the listing of Tecentriq® and Avastin® (atezolizumab and bevacizumab) on the Pharmaceutical Benefits Scheme (PBS).

Related

  • Parliamentary Morning Tea: We can eliminate hepatitis C!

    Parliamentary Morning Tea: We can eliminate hepatitis C!

    The Parliamentary Friends Group for Action of Blood Borne Viruses Co-Chairs, Tim Wilson, MP and Senator Louise Pratt invite you to a Parliamentary Morning Tea on Thursday 12 November.

  • Renewed calls for Needle & Syringe Programs in prisons ahead of International Drug Users Day

    Renewed calls for Needle & Syringe Programs in prisons ahead of International Drug Users Day

    The Australian Injecting and Illicit Drug Users League (AIVL) and Hepatitis Australia are highlighting international calls for Needle and Syringe Programs (NSPs) in prisons, along with a greater focus on harm reduction initiatives, ahead of International Drug Users Day on 1 November.

  • Investment in hepatitis research needs to be accompanied by National Strategy implementation funding

    Investment in hepatitis research needs to be accompanied by National Strategy implementation funding

    6 October 2020 - Hepatitis Australia welcomes the Australian Government’s commitment to diverse hepatitis research, however we remain concerned that the 2019 Health Budget funding for hepatitis commitments is yet to hit the ground.

  • Investment in liver cancer medicines matched with prevention are changing Australian lives

    Investment in liver cancer medicines matched with prevention are changing Australian lives

    6 October 2020 - Hepatitis Australia welcomes the Australian Government’s significant investment of $230 million to expand the listing of Tecentriq® and Avastin® (atezolizumab and bevacizumab) on the Pharmaceutical Benefits Scheme (PBS).

  • 2020 Nobel Prize awarded for discovery of hepatitis C virus

    2020 Nobel Prize awarded for discovery of hepatitis C virus

    6 October 2020 - Hepatitis Australia is celebrating the news that the Nobel Prize in Physiology or Medicine 2020 has been awarded jointly to Harvey J. Alter, Michael Houghton and Charles M. Rice ‘for the discovery of Hepatitis C virus’.

  • Not seeking help may place your health, or your life, at risk.

    Not seeking help may place your health, or your life, at risk.

    Patient safety and continuity of care is extremely important, particularly for people who have chronic and complex diseases or conditions, which is why Hepatitis Australia has joined the Continuity of Care Collaboration

  • Australian First for Network Nurse

    Australian First for Network Nurse

    22 September 2020: Hepatology Nurse Practitioner, Tracey Jones, has become the first Australian nurse to be awarded the Associate Fellow designation from the American Association for the Study of Liver Diseases

  • Let’s Talk Hep on World Hepatitis Day – 28 July

    Let’s Talk Hep on World Hepatitis Day – 28 July

    As Australia grapples with COVID-19 outbreaks, it is important to remember that viral hepatitis is also a pandemic. Viral hepatitis can lead to liver cancer and directly impacts nearly 360,000 people in Australia.

  • Leading organisations unite to discuss COVID-19 impact on hepatitis C elimination in Australia on World Hepatitis Day

    Leading organisations unite to discuss COVID-19 impact on hepatitis C elimination in Australia on World Hepatitis Day

    24 July 2020 - Australia’s leading drug and infectious disease organisations will join forces to call for a re-engagement in elimination of hepatitis C in an online event on World Hepatitis Day, Tuesday, 28 July 2020.

  • Hepatitis C outbreak ignites debate on needle exchange in Queensland correctional centres

    Hepatitis C outbreak ignites debate on needle exchange in Queensland correctional centres

    23 July 2020 - Except from article from ABC Far North about hepatitis C outbreak in Queensland correctional centre.

Most read

  • Coronavirus COVID-19 factsheet for people with hepatitis B and hepatitis C

    Coronavirus COVID-19 factsheet for people with hepatitis B and hepatitis C

    Hepatitis Australia has put together a brief factsheet with information about the coronavirus COVID-19 for people living with hepatitis B and hepatitis C.

  • COVID-19

    COVID-19

    Information on the coronavirus COVID-19 for people affected by hepatitis B or hepatitis C.

  • Hepatitis A

    Basic information about hepatitis A in Australia

  • Hepatitis B and relationships

    Hepatitis B and relationships

    Although most people get hepatitis B at birth, it can be transmitted in other ways including sex. This article contains information about how it is spreads, and how you can keep your partner safe.

  • A cure for hepatitis C

    A cure for hepatitis C

    Highly effective medicines are now available in Australia to cure hepatitis C

  • Hepatitis B treatment

    Hepatitis B treatment

    Who needs treatment for hepatitis B and what is involved.

  • What is hepatitis C?

    What is hepatitis C?

    Basic information about hepatitis C and how it can effect you.

  • Hepatitis B vaccination

    Hepatitis B vaccination

    Hepatitis B can be prevented with a safe and effective vaccine.

  • Accessibility

  • Changes to immigration health requirement a positive move for migrants with hepatitis B

    Changes to immigration health requirement a positive move for migrants with hepatitis B

    21 August 2019 - Changes to the immigration health requirement will have a significant and positive impact for people with hepatitis B seeking to migrate permanently to Australia.

Join our mailing list

Interests

Info

Hepatitis Australia is a registered charity. 
ABN: 38 442 686 487

© Copyright 2019 Hepatitis Australia.
All rights reserved.
View our copyright statement here

Helpful links

  • Contact us
  • Full sitemap
  • Accessibillity
  • Terms & conditions
  • Privacy policy
  • Login
  • Logout
  • Manager

Member sites

  • Australian Capital Territory
  • New South Wales
  • Northern Territory
  • South Australia
  • Victoria
  • Queensland
  • Western Australia
  • Tasmania 

Information provided on this website is for general information only and not intended as medical advice. Hepatitis Australia encourages all readers to seek independent medical advice before making any decisions based on the information provided on this website.

Hepatitis Australia is a partner organisation of healthdirect Australia.
healthdirect - trusted health advice

This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information: verify here.
Search only trustworthy HONcode health websites: 

Images used on this site may include stock photos and the associated messaging may not represent the personal situation, views or beliefs of the people in the images.